U.S. Markets closed

Is Proteostasis Therapeutics Inc (NASDAQ:PTI) Worth US$10.35 Based On Intrinsic Value?

In this article I am going to calculate the intrinsic value of Proteostasis Therapeutics Inc (NASDAQ:PTI) by taking the expected future cash flows and discounting them to today’s value. I will use the discounted cash flows (DCF) model. Don’t get put off by the jargon, the math behind it is actually quite straightforward. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. If you are reading this and its not October 2018 then I highly recommend you check out the latest calculation for Proteostasis Therapeutics by following the link below.

View our latest analysis for Proteostasis Therapeutics

The model

I use what is known as a 2-stage model, which simply means we have two different periods of varying growth rates for the company’s cash flows. Generally the first stage is higher growth, and the second stage is a more stable growth phase. To begin with we have to get estimates of the next five years of cash flows. For this I used the consensus of the analysts covering the stock, as you can see below. The sum of these cash flows is then discounted to today’s value.

5-year cash flow forecast

2019 2020 2021 2022 2023
Levered FCF ($, Millions) $-96.00 $-125.00 $77.00 $57.00 $66.12
Source Analyst x1 Analyst x1 Analyst x1 Analyst x1 Est @ 16%, capped from 16.03%
Present Value Discounted @ 13.02% $-84.94 $-97.85 $53.33 $34.93 $35.85

Present Value of 5-year Cash Flow (PVCF)= -US$59m

After calculating the present value of future cash flows in the intial 5-year period we need to calculate the Terminal Value, which accounts for all the future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at an annual growth rate equal to the 10-year government bond rate of 2.9%. We discount this to today’s value at a cost of equity of 13%.

Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = US$66m × (1 + 2.9%) ÷ (13% – 2.9%) = US$676m

Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = US$676m ÷ ( 1 + 13%)5 = US$366m

The total value is the sum of cash flows for the next five years and the discounted terminal value, which results in the Total Equity Value, which in this case is US$308m. The last step is to then divide the equity value by the number of shares outstanding. If the stock is an depositary receipt (represents a specified number of shares in a foreign corporation) then we use the equivalent number. This results in an intrinsic value of $8.39. Compared to the current share price of $10.35, the stock is fair value, maybe slightly overvalued and not available at a discount at this time.

NasdaqGM:PTI Intrinsic Value Export October 19th 18

Important assumptions

I’d like to point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don’t have to agree with my inputs, I recommend redoing the calculations yourself and playing with them. Because we are looking at Proteostasis Therapeutics as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighed average cost of capital, WACC) which accounts for debt. In this calculation I’ve used 13%, which is based on a levered beta of 1.429. This is derived from the Bottom-Up Beta method based on comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Although the valuation of a company is important, it shouldn’t be the only metric you look at when researching a company. What is the reason for the share price to differ from the intrinsic value? For PTI, there are three pertinent factors you should look at:

  1. Financial Health: Does PTI have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Future Earnings: How does PTI’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of PTI? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St does a DCF calculation for every US stock every 6 hours, so if you want to find the intrinsic value of any other stock just search here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.